论文部分内容阅读
目的 探讨泰胃美在预防危重病患者急性胃粘膜病变并出血的疗效。方法 对 86例危重病患者随机分成 2组 ,其中治疗组 46例加用泰胃美治疗 ,对照组 40例未给任何制酸剂及胃粘膜保护剂 ,分别观察急性胃粘膜病变出血的发生率。结果 泰胃美组中 6例占 13 .0 4% (6/4 6)出现胃粘膜病变并出血 ,对照组 11例占 2 7.5 % (11/4 0 )出现胃粘膜病变并出血。两组经统计学处理有显著差异 (P <0 .0 5 )。结论 泰胃美在预防危重病患者急性胃粘膜病变出血的发生中有良好的疗效
Objective To investigate the effect of Taiweimei on preventing acute gastric mucosal lesions and bleeding in critically ill patients. Methods 86 cases of critically ill patients were randomly divided into two groups, including 46 cases treated with Tai Weimei treatment group, 40 cases of the control group did not give any antacids and gastric mucosal protective agent were observed in the incidence of acute gastric mucosal lesions bleeding . Results In the TST group, 6 cases (13.4%) had gastric mucosal lesion and hemorrhage in 6 cases (11.5%) in the control group, with gastric mucosal lesion and bleeding. The two groups were statistically significant differences (P <0. 05). Conclusion TST is effective in preventing the occurrence of acute gastric mucosal hemorrhage in critically ill patients